Celtic Pharma enrols first patient for fungal nail trial
Celtic Pharmaceutical, a private equity firm focused on the biotechnology and pharmaceutical industries, has enroled the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes, for the topical treatment of onychomycosis or fungal nail infection. The trial is a three-arm, double-blind study to be conducted in
